Caplin Point Laboratories rose 2.66% to Rs 397.55 at 12:29 IST on BSE after the company got Establishment Inspection Report from the USFDA for its sterile injectable site at Gummidopoondi, Tamil Nadu.
The announcement was made during market hours today, 8 May 2017.Meanwhile, the S&P BSE Sensex was up 93.46 points or 0.31% at 29,952.26. The S&P BSE Mid-Cap index was up 83.11 points, or 0.56% at 14,801.59
On BSE, so far 11,000 shares were traded in the counter as against average daily volume of 7,893 shares in the past one quarter. The stock hit a high of Rs 411.95 and a low of Rs 391 so far during the day. The stock hit a record high of Rs 459.70 on 7 February 2017. The stock hit a 52-week low of Rs 184 on 12 May 2016.
The mid-cap company has equity capital of Rs 15.12 crore. Face value per share is Rs 2.
Caplin Point said that the company has received the Establishment Inspection Report (EIR) from USFDA (United States Food and Drug Administration) for inspection carried out during 21 October 2016 to 27 October 2016, at its sterile injectable plant at Gummidopoondi, Tamil Nadu (TN).
Caplin Point Laboratories Chairman C C Paarthipan said that the EIR will pave the way for the company's entry into the largest pharma market in the world.
More From This Section
Caplin Point Laboratories' consolidated net profit rose 48.45% to Rs 23.90 crore on 30.44% growth in total income to Rs 104.99 crore in Q3 December 2016 over Q3 December 2015.
Caplin Point Laboratories is a niche pharmaceutical company, catering predominantly to emerging markets of Latin America and Africa.
Powered by Capital Market - Live News